HIV vaccines: Plan B

| 1 min read

Listen with Speechify

0:00

1:00

linkurl:Anthony Fauci,;http://www.the-scientist.com/article/display/13734/ director of NIH's National Institute of Allergies and Infectious Diseases (NIAID), is apparently making good on the promise to "turn the knob towards discovery" in HIV vaccine research, which he made at a linkurl:meeting;http://www.the-scientist.com/blog/display/54488/ this March. The NIAID today (May 20) linkurl:announced;http://www.nih.gov/news/health/may2008/niaid-20.htm a five-year, $15.6 million project to fund research that aims to elicit the production of broad linkurl:neutralizing antibodies;http://www.the-scientist.com/article/home/39377/ from linkurl:B cells;http://www.the-scientist.com/article/display/19841/ instead of targeting linkurl:T cells;http://www.the-scientist.com/article/display/20089/ - the approach taken by linkurl:previous vaccine efforts.;http://www.the-scientist.com/blog/display/53633/ "This program reflects our commitment to probe the fundamental science underlying HIV vaccine development," Fauci said in an NIAID release. "The study of B cells and broadly neutralizing antibodies to HIV will answer pressing, basic scientific questions and bring greater balance to our portfolio of HIV vaccine discovery research." The 10 research groups funded through the program include investigators at the Scripps Research Institute, the University of California, Irvine, and Weill Cornell Medical College. According to the NIAID, the teams will share data and resources in their quest for a B cell-focused vaccine.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here